Skip to main content

Alterations in coagulation and fibrinolysis after levothyroxine exposure in healthy volunteers: a controlled randomized crossover study.

Van Zaane B, Squizzato A, Debeij J, Dekkers OM, Meijers JC, Van Zanten AP, Büller HR, Gerdes VE, Cannegieter SC, Brandjes DP

Publication: J Thromb Haemost (2011) • Vol 9 • Page 1816-24PMID: 21729238View on PubMed

Purpose

The purpose of this paper was to determine the effects of supraphysiological doses Levothyroxine on coagulation activation and inhibition of fibrinolysis.

Conclusion

Taking Levothyroxine daily led to increased free thyroxine (FT4), tri-iodothyronine (T3), von Willebrand factor (VWF) (antigen and activity), factor VIII, factor IX, factor X, plasminogen activator inhibitor-1 (PAI-1) levels, and clot lysis time and decreased thyroid stimulating hormone (TSH), fibrinogen levels, and activated partial thromboplastin time (APTT) compared to baseline values.

Studies (1)

Purpose

The purpose of this study was to determine the effects of taking Levothyroxine daily on coagulation, fibrinolysis and thyroid status in specimens from healthy volunteers. Fibrinolysis and coagulation parameters were measured in aliquots of citrated plasma stored at -80 degrees C. T3, T4 and TSH were assayed in whole blood on the day of collection. The highest dose of Levothyroxine ingested was 0.45 mg for subjects weighing less than 80 kG and 0.60 mg daily for subjects weighing more than 80 kG.

Summary of Findings

Small increases in FT4 (p<0.01) and T3 (p<0.01) and decreases in TSH (p<0.01) occurred in volunteers taking 0.3 mg Levothyroxine daily compared to levels measured prior to the administration of Levothyroxine. The change in FT4, T3, and TSH levels with exposure to 0.3 mg Levothyroxine caused 5 of 16 previously healthy subjects to have clinically abnormal FT4 and T3 levels and fully suppressed levels of TSH. The higher dose of Levothyroxine (0.45 or 0.60 mg/daily based on body weight) caused a larger increase in FT4 (p<0.01) and T3 (p<0.01) levels and a decrease in TSH (p<0.01), such that all 12 subjects became hyperthyroid, and 8 had fully suppressed TSH. Median VWF antigen and activity, factor VIII, and PAI-1 levels and clot-lysis times were higher after exposure to 0.3 mg Levothyroxine, but only the increase in VWF antigen and activity was significant compared to baseline (each p<0.03). The higher dose of Levothyroxine, significantly increased VWF antigen (p=0.02) and activity (p=0.04), factor VIII (p=0.02), factor VIX (p<0.01), factor X (p=0.05), PAI-1 (p=0.04) and clot lysis time (p<0.01) and decreased fibrinogen (p=002) and shortened APTT (p=0.01). Prothrombin time (PT), factor II, factor VII, total protein S, free Protein S, protein C, activated protein C sensitivity ratio (APC-SR), lag time of endogenous thrombin potential (ETP), peak height of ETP, plasmin-antiplasmin complexes (PAP), prothrombin fragments 1 and 2, and D-dimer were not affected by either dose of Levothyroxine.

  • Biospecimens

    FluidBlood
    FluidPlasma
  • Preservation Types

    FrozenNone (Fresh)
  • Diagnoses

    Normal
  • Platforms

    GlycoproteinImmunoassay
    PeptideImmunoassay
    PeptideHematology/ auto analyzer
    GlycoproteinHematology/ auto analyzer
    ProteinClinical chemistry/auto analyzer
    ProteinHematology/ auto analyzer
    ProteinELISA
    MorphologyHematology/ auto analyzer
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionOther drugs
    0.3 mg Levothyroxin daily
    0.45 mg Levothyroxin daily
    0.60 mg Levothyroxin daily